



# **Funds Range Information France**

**13/05/2025**

Please find below the latest modifications to the CANDRIAM funds range.

The list of ISINs and links for documents to our Candriam site are available in the attached excel file.



## Belgium

### Termination of marketing in France

The following share class **ceased to be authorized** for public marketing in **France** from the **7<sup>th</sup> of May 2025**.

Sub-fund name	Share class	Share type	ISIN
Belfius Equities Immo	C	D	BE0940607956



## Luxembourg

### Merger ratios *(Addendum: notice)*

The Board of Direction of **Candriam Equities L** have decided of the merger of the **LOCK** classes of various sub-funds into the **Classique** class of the same sub-funds:

Sub-fund name	Absorbed Share		Absorbed ISIN	Absorbing share		Absorbed ISIN	Effective merger	Merger ratio
Candriam Equities L Biotechnology	L	C	LU0574798848	C	C	LU0108459040	23-04-25	0.9758453750
Candriam Equities L Emerging Markets	L	C	LU0574798921	C	C	LU0056052961	24-04-25	0.9816072820
Candriam Equities L Europe Innovation	L	C	LU0654531002	C	C	LU0344046155	23-04-25	0.9832307990
Candriam Equities L Europe Optimum Quality	L	C	LU0574799226	C	C	LU0304859712	23-04-25	0.9822418860
Candriam Equities L Global Demography	L	C	LU0654531697	C	C	LU0654531184	23-04-25	0.9878299440

Notice to shareholders	Yes	No	Distribution date
Press information		•	
Individual letter to registered shareholders	•		30/04/2025

This document is published solely for the purposes of information for professional investors (as defined in the section "Legal Information" on our website [www.candriam.com](http://www.candriam.com)), distributors and intermediaries, it contains no offer for the purchase or sale of financial instruments, and it is not confirmation of any transaction unless expressly agreed otherwise. The information contained in this document was obtained from a number of different sources. Although CANDRIAM exercises the greatest care when choosing its sources of information and passing on this information, certain errors or omissions may have escaped our notice. The past performance of a product is by no means a guarantee of future results and the value of investments may increase or decrease. CANDRIAM cannot be held liable for any direct or indirect damage or loss resulting from the use of this document. The contents of this document may be reproduced only with the prior written agreement of CANDRIAM. The intellectual property rights of CANDRIAM must be respected at all times.

This recommendation is an advertising communication as defined in Article 24, §2 of Directive 2006/73/CE dated 10 August 2006 executing Directive 2004/39/CE of the European Parliament and Council. It has not been drawn up in accordance with the legal provisions intended to promote the independence of investment research, and it is not subject to any prohibition of transactions prior to the dissemination of investment research.

